Real-life Effectiveness of Afatinib Versus Gefitinib in
Patients With Non-small-cell Lung Cancer: A Czech Multicentre
Study

J 2021

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

SVATON, Martin, Monika BRATOVÁ, Ondrej FISCHER, Jana KREJCI, Leona KOUBKOVA et. al.

Basic information

Original name

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study

Authors

SVATON, Martin (203 Czech Republic, guarantor), Monika BRATOVÁ (203 Czech Republic, belonging to the institution), Ondrej FISCHER (203 Czech Republic), Jana KREJCI (203 Czech Republic), Leona KOUBKOVA (203 Czech Republic), Marketa CERNOVSKA (203 Czech Republic), Michal HRNCIARIK (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic), Helena ČOUPKOVÁ (203 Czech Republic), Bedrich PORZER (203 Czech Republic), Daniel DOLEZAL (203 Czech Republic), Tana TUZOVA (203 Czech Republic), Karolina HURDALKOVA (203 Czech Republic), Magda BARINOVA (203 Czech Republic) and Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution)

Edition

Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.435

RIV identification code

RIV/00216224:14110/21:00121675

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/anticanres.14975

UT WoS

000637198100006

Keywords in English

Afatinib; gefitinib; NSCLC; real world data

Abstract

V originále

Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. Patients and Methods: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher & rsquo;s exact test. Overall (OS) and progression free (PFS) survival were estimated by Kaplan & ndash;Meier method. Results: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. Conclusion: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.

Citovat

SVATON, Martin, Monika BRATOVÁ, Ondrej FISCHER, Jana KREJCI, Leona KOUBKOVA, Marketa CERNOVSKA, Michal HRNCIARIK, Milada ZEMANOVA, Helena ČOUPKOVÁ, Bedrich PORZER, Daniel DOLEZAL, Tana TUZOVA, Karolina HURDALKOVA, Magda BARINOVA and Jana SKŘIČKOVÁ. Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, vol. 41, No 4, p. 2059-2065. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.14975.

@article{1772601,
   author = {Svaton, Martin and Bratová, Monika and Fischer, Ondrej and Krejci, Jana and Koubkova, Leona and Cernovska, Marketa and Hrnciarik, Michal and Zemanova, Milada and Čoupková, Helena and Porzer, Bedrich and Dolezal, Daniel and Tuzova, Tana and Hurdalkova, Karolina and Barinova, Magda and Skřičková, Jana},
   article_location = {Athens},
   article_number = {4},
   doi = {http://dx.doi.org/10.21873/anticanres.14975},
   keywords = {Afatinib; gefitinib; NSCLC; real world data},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study},
   url = {https://ar.iiarjournals.org/content/41/4/2059},
   volume = {41},
   year = {2021}
}

TY  - JOUR
ID  - 1772601
AU  - Svaton, Martin - Bratová, Monika - Fischer, Ondrej - Krejci, Jana - Koubkova, Leona - Cernovska, Marketa - Hrnciarik, Michal - Zemanova, Milada - Čoupková, Helena - Porzer, Bedrich - Dolezal, Daniel - Tuzova, Tana - Hurdalkova, Karolina - Barinova, Magda - Skřičková, Jana
PY  - 2021
TI  - Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
JF  - Anticancer Research
VL  - 41
IS  - 4
SP  - 2059-2065
EP  - 2059-2065
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Afatinib
KW  - gefitinib
KW  - NSCLC
KW  - real world data
UR  - https://ar.iiarjournals.org/content/41/4/2059
N2  - Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. Patients and Methods: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher & rsquo;s exact test. Overall (OS) and progression free (PFS) survival were estimated by Kaplan & ndash;Meier method. Results: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. Conclusion: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
ER  -

SVATON, Martin, Monika BRATOVÁ, Ondrej FISCHER, Jana KREJCI, Leona KOUBKOVA, Marketa CERNOVSKA, Michal HRNCIARIK, Milada ZEMANOVA, Helena ČOUPKOVÁ, Bedrich PORZER, Daniel DOLEZAL, Tana TUZOVA, Karolina HURDALKOVA, Magda BARINOVA and Jana SKŘIČKOVÁ. Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, vol.~41, No~4, p.~2059-2065. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.14975.

Detailed Information on Publication Record